|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: loteprednol etabonate
| |||||||||||||||||||||
Clinical Trials for: loteprednol etabonateLoteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge Status: Completed Condition: Allergic Conjunctivitis Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Status: Completed Condition: Dry Eye Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% Status: Active, not recruiting Condition: Dry Eyes Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis Status: Active, not recruiting Condition: Meibomian Gland Dysfunction; Posterior Blepharitis Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Status: Completed Condition: Allergic Conjunctivitis Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Status: Completed Condition: Conjunctivitis Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery Status: Completed Condition: Ocular Inflammation Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery Status: Completed Condition: Inflammation; Pain Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca Status: Recruiting Condition: Keratoconjunctivitis Sicca A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin Status: Completed Condition: Ocular Hypertension Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb | LOTEMAX | loteprednol etabonate | GEL; OPHTHALMIC | 202872 | Sep 28, 2012 | RX | Yes | 5,800,807 | Y | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | LOTEMAX | loteprednol etabonate | GEL; OPHTHALMIC | 202872 | Sep 28, 2012 | RX | Yes | <disabled> | NEW DOSAGE FORM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | LOTEMAX | loteprednol etabonate | OINTMENT; OPHTHALMIC | 200738 | Apr 15, 2011 | RX | Yes | <disabled> | NEW DOSAGE FORM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch And Lomb | LOTEMAX | loteprednol etabonate | OINTMENT; OPHTHALMIC | 200738 | Apr 15, 2011 | RX | Yes | <disabled> | PEDIATRIC EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
